Clinical Trial Update: Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Open-label safety and efficacy study of QRX003 Lotion in Netherton syndrome; Phase 2/Phase 3, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Netherton Syndrome

Drugs mentioned

• QRX003 Lotion

Snippet

Sponsor: Quoin Pharmaceuticals | Conditions: Netherton Syndrome | Phase 2, Phase 3 | Status: RECRUITING